Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.91 USD | -0.44% | +10.02% | +63.31% |
19/04 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
28/03 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
Business Summary
Number of employees: 201
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Therapeutics
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Netherlands
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bill Lundberg
CEO | Chief Executive Officer | 60 | 12/19/12 |
Gregory Perry
DFI | Director of Finance/CFO | 63 | 01/16/01 |
Chief Tech/Sci/R&D Officer | - | 01/16/01 | |
Chief Tech/Sci/R&D Officer | 56 | 01/21/01 | |
Andrew Joe
CTO | Chief Tech/Sci/R&D Officer | 58 | 27/20/27 |
Peter Silverman
COO | Chief Operating Officer | 46 | 01/17/01 |
John de Kruif
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/07/01 |
Sherri L. Spear
IRC | Investor Relations Contact | - | - |
Ashley Pereira
LAW | General Counsel | - | 01/21/01 |
Shannon Campbell
PRN | Corporate Officer/Principal | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Perry
DFI | Director of Finance/CFO | 63 | 01/16/01 |
Maxine Gowen
BRD | Director/Board Member | 66 | 28/21/28 |
Paolo Pucci
BRD | Director/Board Member | 63 | 30/20/30 |
Anand Mehra
CHM | Chairman | 48 | 26/15/26 |
Mark Iwicki
BRD | Director/Board Member | 57 | 01/15/01 |
Bill Lundberg
CEO | Chief Executive Officer | 60 | 12/19/12 |
Victor Sandor
BRD | Director/Board Member | 57 | 12/19/12 |
Len Kanavy
BRD | Director/Board Member | 62 | 01/18/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,687,551 | 54,301,344 ( 92.53 %) | 0 | 92.53 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.31% | 2.65B | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- MRUS Stock
- Company Merus N.V.